Mitochondrial dysfunction and tissue injury by alcohol, high fat, nonalcoholic substances and pathological conditions through post-translational protein modifications

Redox Biology

Volumn 3, Issue , 2014, Pages 109-123

  Song, Byoung Joon ^a   Akbar, Mohammed ^a   Abdelmegeed, Mohamed A ^a   Byun, Kyunghee ^b   Lee, Bonghee ^b   Yoon, Seung Kew ^c   Hardwick, James P ^d  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b Gachon University   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d Northeast Ohio Medical University   (United States)

Author keywords

Mitochondrial dysfunction; Mitochondrial proteins; Nitroxidative stress; Post translational modifications; Redox; Tissue injury

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CYTOCHROME P450 2E1; MITOCHONDRIAL PROTEIN; ALCOHOL; ANTIOXIDANT;

ARTICLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA ADDUCT; ENZYME INDUCTION; HUMAN; LIPID STORAGE; MOLECULAR PATHOLOGY; NITRATION; NONHUMAN; OXIDATION; PROTEIN ACETYLATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; TISSUE INJURY; TRANSLATIONAL RESEARCH; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; LIPID DIET; LIVER DISEASES; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; PROTEIN PROCESSING;

ANIMALS; ANTIOXIDANTS; DIET, HIGH-FAT; ETHANOL; HUMANS; LIVER DISEASES; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84918551836     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.10.004     Document Type: Article

References (242)

1. Soboll S. Regulation of energy metabolism in liver. Journal of Bioenergetics and Biomembranes 1995, 27(6):571-582. http://www.ncbi.nlm.nih.gov/pubmed/8746844, 10.1007/BF02111655.
2. Dimmer K.S., Scorrano L. (De)constructing mitochondria: What for?. Physiology (Bethesda, Md.) 2006, 21:233-241. http://www.ncbi.nlm.nih.gov/pubmed/16868312, 10.1152/physiol.00010.2006.
3. Galloway C.A., Yoon Y. Mitochondrial morphology in metabolic diseases. Antioxidants and Redox Signaling 2013, 19(4):415-430. http://www.ncbi.nlm.nih.gov/pubmed/22793999, 10.1089/ars.2012.4779.
4. Hoek J.B., Cahill A., Pastorino J.G. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology 2002, 122(7):2049-2063. http://www.ncbi.nlm.nih.gov/pubmed/12055609, 10.1053/gast.2002.33613.
5. Mantena S.K., King A.L., Andringa K.K., Eccleston H.B., Bailey S.M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radical Biology & Medicine 2008, 44(7):1259-1272. http://www.ncbi.nlm.nih.gov/pubmed/18242193, 10.1016/j.freeradbiomed.2007.12.029.
6. Wu D., Cederbaum A.I. Oxidative stress and alcoholic liver disease. Seminars in Liver Disease 2009, 29(2):141-154. http://www.ncbi.nlm.nih.gov/pubmed/19387914, 10.1055/s-0029-1214370.
7. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., Clore J.N. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120(5):1183-1192. http://www.ncbi.nlm.nih.gov/pubmed/11266382, 10.1053/gast.2001.23256.
8. Gambino R., Musso G., Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: Mechanisms and therapeutic opportunities. Antioxidants and Redox Signaling 2011, 15(5):1325-1365. http://www.ncbi.nlm.nih.gov/pubmed/20969475, 10.1089/ars.2009.3058.
9. Blake R., Trounce I.A. Mitochondrial dysfunction and complications associated with diabetes. Biochimica et Biophysica Acta 2014, 1840(4):1404-1412. http://www.ncbi.nlm.nih.gov/pubmed/24246956, 10.1016/j.bbagen.2013.11.007.
10. Wallace D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annual Review of Genetics 2005, 39:359-407. http://www.ncbi.nlm.nih.gov/pubmed/16285865, 10.1146/annurev.genet.39.110304.095751.
11. Chaturvedi R.K., Flint Beal M.. Mitochondrial diseases of the brain. Free Radical Biology and Medicine 2013, 63:1-29. http://www.ncbi.nlm.nih.gov/pubmed/23567191, 10.1016/j.freeradbiomed.2013.03.018.
12. Dexter D.T., Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radical Biology and Medicine 2013, 62:132-144. http://www.ncbi.nlm.nih.gov/pubmed/23380027, 10.1016/j.freeradbiomed.2013.01.018.
13. Purohit V., Gao B., Song B.J. Molecular mechanisms of alcoholic fatty liver. Alcoholism, Clinical and Experimental Research 2009, 33(2):191-205. http://www.ncbi.nlm.nih.gov/pubmed/19032584, 10.1111/j.1530-0277.2008.00827.x.
14. Gao B., Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011, 141(5):1572-1585. http://www.ncbi.nlm.nih.gov/pubmed/21920463, 10.1053/j.gastro.2011.09.002.
15. Barnes M.A., Roychowdhury S., Nagy L.E. Innate immunity and cell death in alcoholic liver disease: role of cytochrome P4502E1. Redox Biology 2014, 2:929-935. http://www.ncbi.nlm.nih.gov/pubmed/25180169, 10.1016/j.redox.2014.07.007.
16. Powell C.L., Kosyk O., Bradford B.U., Parker J.S., Lobenhofer E.K., Denda A., Uematsu F., Nakae D., Rusyn I. Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury. Hepatology (Baltimore, Md.) 2005, 42(5):1137-1147. http://www.ncbi.nlm.nih.gov/pubmed/16250055, 10.1002/hep.20910.
17. Baffy G., Brunt E.M., Caldwell S.H. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. Journal of Hepatology 2012, 56(6):1384-1391. http://www.ncbi.nlm.nih.gov/pubmed/22326465, 10.1016/j.jhep.2011.10.027.
18. Cover C., Mansouri A., Knight T.R., Bajt M.L., Lemasters J.J., Pessayre D., Jaeschke H. Peroxynitrite-induced mitochondrial and endonuclease-mediated nuclear DNA damage in acetaminophen hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics 2005, 315(2):879-887. http://www.ncbi.nlm.nih.gov/pubmed/16081675, 10.1124/jpet.105.088898.
19. Jaeschke H., McGill M.R., Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metabolism Reviews 2012, 44(1):88-106. http://www.ncbi.nlm.nih.gov/pubmed/22229890, 10.3109/03602532.2011.602688.
20. Han D., Dara L., Win S., Than T.A., Yuan L., Abbasi S.Q., Liu Z.X., Kaplowitz N. Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends in Pharmacological Sciences 2013, 34(4):243-253. http://www.ncbi.nlm.nih.gov/pubmed/23453390, 10.1016/j.tips.2013.01.009.
21. Ribeiro M.P., Santos A.E., Custódio J.B. Mitochondria: the gateway for tamoxifen-induced liver injury. Toxicology 2014, 323:10-18. http://www.ncbi.nlm.nih.gov/pubmed/24881593, 10.1016/j.tox.2014.05.009.
22. Banerjee A., Abdelmegeed M.A., Jang S., Song B.J. Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators. PloS One 2013, 8(10):e76850. http://www.ncbi.nlm.nih.gov/pubmed/24146933, 10.1371/journal.pone.0076850.
23. Li Y., Couch L., Higuchi M., Fang J.L., Guo L. Mitochondrial dysfunction induced by sertraline, an antidepressant agent. Toxicological Sciences: an Official Journal of the Society of Toxicology 2012, 127(2):582-591. http://www.ncbi.nlm.nih.gov/pubmed/22387747, 10.1093/toxsci/kfs100.
24. Pessayre D., Fromenty B., Berson A., Robin M.A., Lettéron P., Moreau R., Mansouri A. Central role of mitochondria in drug-induced liver injury. Drug Metabolism Reviews 2012, 44(1):34-87. http://www.ncbi.nlm.nih.gov/pubmed/21892896, 10.3109/03602532.2011.604086.
25. Yuan L., Kaplowitz N. Mechanisms of drug-induced liver injury. Clinics in Liver Disease 2013, 17(4):507-518. http://www.ncbi.nlm.nih.gov/pubmed/24099014, 10.1016/j.cld.2013.07.002.
26. Song B.J., Abdelmegeed M.A., Henderson L.E., Yoo S.H., Wan J., Purohit V., Hardwick J.P., Moon K.H. Increased nitroxidative stress promotes mitochondrial dysfunction in alcoholic and nonalcoholic fatty liver disease. Oxidative Medicine and Cellular Longevity 2013, 2013:781050. http://www.ncbi.nlm.nih.gov/pubmed/23691267, 10.1155/2013/781050.
27. Abdelmegeed M.A., Song B.J. Functional roles of protein nitration in acute and chronic liver diseases. Oxidative Medicine and Cellular Longevity 2014, 2014:1-21. 10.1155/2014/149627.
28. Rhee S.G. Cell signaling. H2O2, a necessary evil for cell signaling. Science (New York, N.Y.) 2006, 312(5782):1882-1883. http://www.ncbi.nlm.nih.gov/pubmed/16809515, 10.1126/science.1130481.
29. Hamanaka R.B., Chandel N.S. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends in Biochemical Sciences 2010, 35(9):505-513. http://www.ncbi.nlm.nih.gov/pubmed/20430626, 10.1016/j.tibs.2010.04.002.
30. Von Montfort C., Matias N., Fernandez A., Fucho R., Conde de la Rosa L., Martinez-Chantar M.L., Mato J.M., Machida K., Tsukamoto H., Murphy M.P., Mansouri A., Kaplowitz N., Garcia-Ruiz C., Fernandez-Checa J.C. Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis. Journal of Hepatology 2012, 57(4):852-859. http://www.ncbi.nlm.nih.gov/pubmed/22687340, 10.1016/j.jhep.2012.05.024.
31. Bastidas A.C., Pierce L.C., Walker R.C., Johnson D.A., Taylor S.S. Influence of N-myristylation and ligand binding on the flexibility of the catalytic subunit of protein kinase A. Biochemistry 2013, 52(37):6368-6379. http://www.ncbi.nlm.nih.gov/pubmed/24003983, 10.1021/bi400575k.
32. Nadolski M.J., Linder M.E. Protein lipidation. FEBS Journal 2007, 274(20):5202-5210. http://www.ncbi.nlm.nih.gov/pubmed/17892486, 10.1111/j.1742-4658.2007.06056.x.
33. Song B.J., Suh S.K., Moon K.H. A simple method to systematically study oxidatively modified proteins in biological samples and its applications. Methods in Enzymology 2010, 473:251-264. http://www.ncbi.nlm.nih.gov/pubmed/20513482, 10.1016/S0076-6879(10)73013-5.
34. Moon K.H., Hood B.L., Kim B.J., Hardwick J.P., Conrads T.P., Veenstra T.D., Song B.J. Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology (Baltimore, Md.) 2006, 44(5):1218-1230. http://www.ncbi.nlm.nih.gov/pubmed/17058263, 10.1002/hep.21372.
35. Kim B.J., Hood B.L., Aragon R.A., Hardwick J.P., Conrads T.P., Veenstra T.D., Song B.J. Increased oxidation and degradation of cytosolic proteins in alcohol-exposed mouse liver and hepatoma cells. Proteomics 2006, 6(4):1250-1260. http://www.ncbi.nlm.nih.gov/pubmed/16408314, 10.1002/pmic.200500447.
36. Bai J., Cederbaum A.I. Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against cytochrome P450 2E1-dependent toxicity in HepG2 cells. Journal of Biological Chemistry 2001, 276(6):4315-4321. http://www.ncbi.nlm.nih.gov/pubmed/11071897, 10.1074/jbc.M008895200.
37. Suh S.K., Hood B.L., Kim B.J., Conrads T.P., Veenstra T.D., Song B.J. Identification of oxidized mitochondrial proteins in alcohol-exposed human hepatoma cells and mouse liver. Proteomics 2004, 4(11):3401-3412. http://www.ncbi.nlm.nih.gov/pubmed/15449375, 10.1002/pmic.200400971.
38. Moon K.H., Hood B.L., Mukhopadhyay P., Rajesh M., Abdelmegeed M.A., Kwon Y.I., Conrads T.P., Veenstra T.D., Song B.J., Pacher P. Oxidative inactivation of key mitochondrial proteins leads to dysfunction and injury in hepatic ischemia reperfusion. Gastroenterology 2008, 135(4):1344-1357. http://www.ncbi.nlm.nih.gov/pubmed/18778711, 10.1053/j.gastro.2008.06.048.
39. Moon K.H., Upreti V.V., Yu L.R., Lee I.J., Ye X., Eddington N.D., Veenstra T.D., Song B.J. Mechanism of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated mitochondrial dysfunction in rat liver. Proteomics 2008, 8(18):3906-3918. http://www.ncbi.nlm.nih.gov/pubmed/18780394, 10.1002/pmic.200800215.
40. Pagliarini D.J., Calvo S.E., Chang B., Sheth S.A., Vafai S.B., Ong S.E., Walford G.A., Sugiana C., Boneh A., Chen W.K. A mitochondrial protein compendium elucidates complex I disease biology. Cell 2008, 134(1):112-123. 1098 proteins. http://www.ncbi.nlm.nih.gov/pubmed/18614015, 10.1016/j.cell.2008.06.016.
41. Calvo S.E., Mootha V.K. The mitochondrial proteome and human disease. Annual Review of Genomics and Human Genetics 2010, 11:25-44. http://www.ncbi.nlm.nih.gov/pubmed/20690818, 10.1146/annurev-genom-082509-141720.
42. Song B.J., Abdelmegeed M.A., Yoo S.-H., Kim B.-J., Jo S.A., Jo I., Moon K.-H. Post-translational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications. Journal of Proteomics 2011, 74(12):2691-2702. http://www.ncbi.nlm.nih.gov/pubmed/21609791, 10.1016/j.jprot.2011.05.013.
43. Moon K.H., Kim B.J., Song B.J. Inhibition of mitochondrial aldehyde dehydrogenase by nitric oxide-mediated S-nitrosylation. FEBS Letters 2005, 579(27):6115-6120. http://www.ncbi.nlm.nih.gov/pubmed/16242127, 10.1016/j.febslet.2005.09.082.
44. Venkatraman A., Landar A., Davis A.J., Ulasova E., Page G., Murphy M.P., Darley-Usmar V., Bailey S.M. Oxidative modification of hepatic mitochondria protein thiols: effect of chronic alcohol consumption. American Journal of Physiology. Gastrointestinal and Liver Physiology 2004, 286(4):G521-G527. http://www.ncbi.nlm.nih.gov/pubmed/14670822, 10.1152/ajpgi.00399.2003.
45. Venkatraman A., Landar A., Davis A.J., Chamlee L., Sanderson T., Kim H., Page G., Pompilius M., Ballinger S., Darley-Usmar V., Bailey S.M. Modification of the mitochondrial proteome in response to the stress of ethanol-dependent hepatotoxicity. Journal of Biological Chemistry 2004, 279(21):22092-22101. http://www.ncbi.nlm.nih.gov/pubmed/15033988, 10.1074/jbc.M402245200.
46. Hartley D.P., Ruth J.A., Petersen D.R. The hepatocellular metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase, and glutathione S-transferase. Archives of Biochemistry and Biophysics 1995, 316(1):197-205. http://www.ncbi.nlm.nih.gov/pubmed/7840616, 10.1006/abbi.1995.1028.
47. Bae S.H., Sung S.H., Cho E.J., Lee S.K., Lee H.E., Woo H.A., Yu D.Y., Kil I.S., Rhee S.G. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology (Baltimore, Md.) 2011, 53(3):945-953. http://www.ncbi.nlm.nih.gov/pubmed/21319188, 10.1002/hep.24104.
48. Rhee S.G., Woo H.A., Kil I.S., Bae S.H. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. Journal of Biological Chemistry 2012, 287(7):4403-4410. http://www.ncbi.nlm.nih.gov/pubmed/22147704, 10.1074/jbc.R111.283432.
49. 2, and protein chaperones. Antioxidants and Redox Signaling 2011, 15(3):781-794. http://www.ncbi.nlm.nih.gov/pubmed/20919930, 10.1089/ars.2010.3393.
50. +-dependent isocitrate dehydrogenase. Journal of Biological Chemistry 2001, 276(19):16168-16176. http://www.ncbi.nlm.nih.gov/pubmed/11278619, 10.1074/jbc.M010120200.
51. Lee S.M., Koh H.J., Park D.C., Song B.J., Huh T.L., Park J.W. Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radical Biology and Medicine 2002, 32(11):1185-1196. http://www.ncbi.nlm.nih.gov/pubmed/12031902.
52. Yang E.S., Richter C., Chun J.S., Huh T.L., Kang S.S., Park J.W. Inactivation of NADP(+)-dependent isocitrate dehydrogenase by nitric oxide. Free Radical Biology and Medicine 2002, 33(7):927-937. http://www.ncbi.nlm.nih.gov/pubmed/12361803.
53. +-dependent isocitrate dehydrogenase by peroxynitrite. Implications for cytotoxicity and alcohol-induced liver injury. Journal of Biological Chemistry 2003, 278(51):51360-51371. http://www.ncbi.nlm.nih.gov/pubmed/14551203, 10.1074/jbc.M302332200.
54. 6-methylguanine-DNA-methyltransferase. Carcinogenesis 1994, 15:443-447.
55. Marinho H.S., Real C., Cyrne L., Soares H., Antunes F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biology 2014, 2:535-562. http://www.ncbi.nlm.nih.gov/pubmed/24634836, 10.1016/j.redox.2014.02.006.
56. Cohen J.I., Chen X., Nagy L.E. Redox signaling and the innate immune system in alcoholic liver disease. Antioxidants and Redox Signaling 2011, 15(2):523-534. http://www.ncbi.nlm.nih.gov/pubmed/21126203, 10.1089/ars.2010.3746.
57. Nath B., Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. Hepatology (Baltimore, Md.) 2012, 55(2):622-633. http://www.ncbi.nlm.nih.gov/pubmed/22120903, 10.1002/hep.25497.
58. Zelickson B.R., Benavides G.A., Johnson M.S., Chacko B.K., Venkatraman A., Landar A., Betancourt A.M., Bailey S.M., Darley-Usmar V.M. Nitric oxide and hypoxia exacerbate alcohol-induced mitochondrial dysfunction in hepatocytes. Biochimica et Biophysica Acta 2011, 1807(12):1573-1582. http://www.ncbi.nlm.nih.gov/pubmed/21971515, 10.1016/j.bbabio.2011.09.011.
59. Wang X., Wu D., Yang L., Gan L., Cederbaum A.I. Cytochrome P450 2E1 potentiates ethanol induction of hypoxia and HIF-1α in vivo. Free Radical Biology and Medicine 2013, 63:175-186. http://www.ncbi.nlm.nih.gov/pubmed/23669278, 10.1016/j.freeradbiomed.2013.05.009.
60. Zhou J.Y., Jiang Z.A., Zhao C.Y., Zhen Z., Wang W., Nanji A.A. Long-term binge and escalating ethanol exposure causes necroinflammation and fibrosis in rat liver. Alcoholism, Clinical and Experimental Research 2013, 37(2):213-222. http://www.ncbi.nlm.nih.gov/pubmed/23009062, 10.1111/j.1530-0277.2012.01936.x.
61. Yun J.W., Son M.J., Abdelmegeed M.A., Banerjee A., Morgan T.R., Yoo S.H., Song B.J. Binge alcohol promotes hypoxic liver injury through CYP2E1-HIF1a-dependent apoptosis pathway in mice and humans. Free Radical Biology and Medicine 2014, 77:183-194. (Pubmed: 25236742). 10.1016/j.freeradbiomed.2014.08.030.
62. Gong P., Cederbaum A.I. Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology (Baltimore, Md.) 2006, 43(1):144-153. http://www.ncbi.nlm.nih.gov/pubmed/16374848, 10.1002/hep.21004.
63. Wang Z., Dou X., Li S., Zhang X., Sun X., Zhou Z., Song Z. Nuclear factor (erythroid-derived 2)-like 2 activation-induced hepatic very-low-density lipoprotein receptor overexpression in response to oxidative stress contributes to alcoholic liver disease in mice. Hepatology (Baltimore, Md.) 2014, 59(4):1381-1392. http://www.ncbi.nlm.nih.gov/pubmed/24170703, 10.1002/hep.26912.
64. Kathirvel E., Chen P., Morgan K., French S.W., Morgan T.R. Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. Journal of Gastroenterology and Hepatology 2010, 25(6):1136-1143. http://www.ncbi.nlm.nih.gov/pubmed/20594230, 10.1111/j.1440-1746.2009.06196.x.
65. Xu W., Shao L., Zhou C., Wang H., Guo J. Upregulation of Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. Hepato-Gastroenterology 2011, 58(112):2077-2080. http://www.ncbi.nlm.nih.gov/pubmed/22024078, 10.5754/hge10501.
66. Niture S.K., Khatri R., Jaiswal A.K. Regulation of Nrf2-an update. Free Radical Biology and Medicine 2014, 66:36-44. http://www.ncbi.nlm.nih.gov/pubmed/23434765, 10.1016/j.freeradbiomed.2013.02.008.
67. Grek C.L., Zhang J., Manevich Y., Townsend D.M., Tew K.D. Causes and consequences of cysteine S-glutathionylation. Journal of Biological Chemistry 2013, 288(37):26497-26504. http://www.ncbi.nlm.nih.gov/pubmed/23861399, 10.1074/jbc.R113.461368.
68. Gould N., Doulias P.T., Tenopoulou M., Raju K., Ischiropoulos H. Regulation of protein function and signaling by reversible cysteine S-nitrosylation. Journal of Biological Chemistry 2013, 288(37):26473-26479. http://www.ncbi.nlm.nih.gov/pubmed/23861393, 10.1074/jbc.R113.460261.
69. Sun J., Morgan M., Shen R.F., Steenbergen C., Murphy E. Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circulation Research 2007, 101(11):1155-1163. http://www.ncbi.nlm.nih.gov/pubmed/17916778, 10.1161/CIRCRESAHA.107.155879.
70. Kohr M.J., Sun J., Aponte A., Wang G., Gucek M., Murphy E., Steenbergen C. Simultaneous measurement of protein oxidation and S-nitrosylation during preconditioning and ischemia/reperfusion injury with resin-assisted capture. Circulation Research 2011, 108(4):418-426. http://www.ncbi.nlm.nih.gov/pubmed/21193739, 10.1161/CIRCRESAHA.110.232173.
71. Murphy E., Kohr M., Sun J., Nguyen T., Steenbergen C. S-nitrosylation: a radical way to protect the heart. Journal of Molecular and Cellular Cardiology 2012, 52(3):568-577. http://www.ncbi.nlm.nih.gov/pubmed/21907718, 10.1016/j.yjmcc.2011.08.021.
72. Mailloux R.J., Jin X., Willmore W.G. Redox regulation of mitochondrial function with emphasis on cysteine oxidation reactions. Redox Biology 2014, 2:123-139. http://www.ncbi.nlm.nih.gov/pubmed/24455476, 10.1016/j.redox.2013.12.011.
73. Lu J., Holmgren A. The thioredoxin antioxidant system. Free Radical Biology and Medicine 2014, 66:75-87. http://www.ncbi.nlm.nih.gov/pubmed/23899494, 10.1016/j.freeradbiomed.2013.07.036.
74. Pastore A., Piemonte F. S-glutathionylation signaling in cell biology: progress and prospects. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences 2012, 46(5):279-292. http://www.ncbi.nlm.nih.gov/pubmed/22484331, 10.1016/j.ejps.2012.03.010.
75. Calcerrada P., Peluffo G., Radi R. Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications. Current Pharmaceutical Design 2011, 17(35):3905-3932. http://www.ncbi.nlm.nih.gov/pubmed/21933142, 10.2174/138161211798357719.
76. Brenner C., Galluzzi L., Kepp O., Kroemer G. Decoding cell death signals in liver inflammation. Journal of Hepatology 2013, 59(3):583-594. http://www.ncbi.nlm.nih.gov/pubmed/23567086, 10.1016/j.jhep.2013.03.033.
77. Radi R., Beckman J.S., Bush K.M., Freeman B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. Journal of Biological Chemistry 1991, 266(7):4244-4250. http://www.ncbi.nlm.nih.gov/pubmed/1847917.
78. Wan J., Bae M.A., Song B.J. Acetoaminophen-induced accumulation of 8-oxodeoxyguanosine through reduction of Ogg1 DNA repair enzyme in C6 glioma cells. Experimental and Molecular Medicine 2004, 36(1):71-77. http://www.ncbi.nlm.nih.gov/pubmed/15031674, 10.1038/emm.2004.10.
79. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6(1):1-28. http://www.ncbi.nlm.nih.gov/pubmed/16406828, 10.1016/j.mito.2005.10.004.
80. Elfering S.L., Haynes V.L., Traaseth N.J., Ettl A., Giulivi C. Aspects, mechanism, and biological relevance of mitochondrial protein nitration sustained by mitochondrial nitric oxide synthase. American Journal of Physiology: Heart and Circulatory Physiology 2004, 286(1):H22-H29. http://www.ncbi.nlm.nih.gov/pubmed/14527943, 10.1152/ajpheart.00766.2003.
81. Pickering A.M., Davies K.J. Degradation of damaged proteins: the main function of the 20S proteasome. Progress in Molecular Biology and Translational Science 2012, 109:227-248. http://www.ncbi.nlm.nih.gov/pubmed/22727423, 10.1016/B978-0-12-397863-9.00006-7.
82. Wallace K.B. Mitochondrial off targets of drug therapy. Trends in Pharmacological Sciences 2008, 29(7):361-366. http://www.ncbi.nlm.nih.gov/pubmed/18501972, 10.1016/j.tips.2008.04.001.
83. Chandra D., Singh K.K. Genetic insights into OXPHOS defect and its role in cancer. Biochimica et Biophysica Acta 2011, 1807(6):620-625. http://www.ncbi.nlm.nih.gov/pubmed/21074512, 10.1016/j.bbabio.2010.10.023.
84. Fromenty B., Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. Journal of Hepatology 1997, 26(Suppl. 2):43-53. http://www.ncbi.nlm.nih.gov/pubmed/9204409.
85. Song B.J., Moon K.H., Upreti V.V., Eddington N.D., Lee I.J. Mechanisms of MDMA (ecstasy)-induced oxidative stress, mitochondrial dysfunction, and organ damage. Current Pharmaceutical Biotechnology 2010, 11(5):434-443. http://www.ncbi.nlm.nih.gov/pubmed/20420575.
86. McKim S.E., Gäbele E., Isayama F., Lambert J.C., Tucker L.M., Wheeler M.D., Connor H.D., Mason R.P., Doll M.A., Hein D.W., Arteel G.E. Inducible nitric oxide synthase is required in alcohol-induced liver injury: studies with knockout mice. Gastroenterology 2003, 125(6):1834-1844. http://www.ncbi.nlm.nih.gov/pubmed/14724835, 10.1053/j.gastro.2003.08.030.
87. Venkatraman A., Shiva S., Davis A.J., Bailey S.M., Brookes P.S., Darley-Usmar V.M. Chronic alcohol consumption increases the sensitivity of rat liver mitochondrial respiration to inhibition by nitric oxide. Hepatology (Baltimore, Md.) 2003, 38(1):141-147. http://www.ncbi.nlm.nih.gov/pubmed/12829996, 10.1053/jhep.2003.50293.
88. Venkatraman A., Shiva S., Wigley A., Ulasova E., Chhieng D., Bailey S.M., Darley-Usmar V.M. The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. Hepatology (Baltimore, Md.) 2004, 40(3):565-573. http://www.ncbi.nlm.nih.gov/pubmed/15349894, 10.1002/hep.20326.
89. Mantena S.K., Vaughn D.P., Andringa K.K., Eccleston H.B., King A.L., Abrams G.A., Doeller J.E., Kraus D.W., Darley-Usmar V.M., Bailey S.M. High fat diet induces dysregulation of hepatic oxygen gradients and mitochondrial function in vivo. Biochemical Journal 2009, 417(1):183-193. http://www.ncbi.nlm.nih.gov/pubmed/18752470, 10.1042/BJ20080868.
90. Spruss A., Kanuri G., Uebel K., Bischoff S.C., Bergheim I. Role of the inducible nitric oxide synthase in the onset of fructose-induced steatosis in mice. Antioxidants and Redox Signaling 2011, 14(11):2121-2135. http://www.ncbi.nlm.nih.gov/pubmed/21083420, 10.1089/ars.2010.3263.
91. Hinson J.A., Pike S.L., Pumford N.R., Mayeux P.R. Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. Chemical Research in Toxicology 1998, 11(6):604-607. http://www.ncbi.nlm.nih.gov/pubmed/9625727, 10.1021/tx9800349.
92. Knight T.R., Ho Y.S., Farhood A., Jaeschke H. Peroxynitrite is a critical mediator of acetaminophen hepatotoxicity in murine livers: protection by glutathione. Journal of Pharmacology and Experimental Therapeutics 2002, 303(2):468-475. http://www.ncbi.nlm.nih.gov/pubmed/12388625, 10.1124/jpet.102.038968.
93. Abdelmegeed M.A., Moon K.H., Chen C., Gonzalez F.J., Song B.J. Role of cytochrome P450 2E1 in protein nitration and ubiquitin-mediated degradation during acetaminophen toxicity. Biochemical Pharmacology 2010, 79(1):57-66. http://www.ncbi.nlm.nih.gov/pubmed/19660437, 10.1016/j.bcp.2009.07.016.
94. Abdelmegeed M.A., Jang S., Banerjee A., Hardwick J.P., Song B.J. Robust protein nitration contributes to acetaminophen-induced mitochondrial dysfunction and acute liver injury. Free Radical Biology and Medicine 2013, 60:211-222. http://www.ncbi.nlm.nih.gov/pubmed/23454065, 10.1016/j.freeradbiomed.2013.02.018.
95. Yun J.W., Lum K., Lei X.G. A novel upregulation of glutathione peroxidase 1 by knockout of liver-regenerating protein Reg3β aggravates acetaminophen-induced hepatic protein nitration. Free Radical Biology and Medicine 2013, 65:291-300. http://www.ncbi.nlm.nih.gov/pubmed/23811004, 10.1016/j.freeradbiomed.2013.06.034.
96. Yoo S.H., Park O., Henderson L.E., Abdelmegeed M.A., Moon K.H., Song B.J. Lack of PPARα exacerbates lipopolysaccharide-induced liver toxicity through STAT1 inflammatory signaling and increased oxidative/nitrosative stress. Toxicology Letters 2011, 202(1):23-29. http://www.ncbi.nlm.nih.gov/pubmed/21262334, 10.1016/j.toxlet.2011.01.013.
97. Nuriel T., Hansler A., Gross S.S. Protein nitrotryptophan: formation, significance and identification. Journal of Proteomics 2011, 74(11):2300-2312. http://www.ncbi.nlm.nih.gov/pubmed/21679780, 10.1016/j.jprot.2011.05.032.
98. Bregere C., Rebrin I., Sohal R.S. Detection and characterization of in vivo nitration and oxidation of tryptophan residues in proteins. Methods in Enzymology 2008, 441:339-349. http://www.ncbi.nlm.nih.gov/pubmed/18554544, 10.1016/S0076-6879(08)01219-6.
99. Yamakura F., Kawasaki H. Post-translational modifications of superoxide dismutase. Biochimica et Biophysica Acta 2010, 1804(2):318-325. http://www.ncbi.nlm.nih.gov/pubmed/19837190, 10.1016/j.bbapap.2009.10.010.
100. Ron D., Messing R.O. Signaling pathways mediating alcohol effects. Current Topics in Behavioral Neuroscience 2013, 13:87-126.
101. Sid B., Verrax J., Calderon P.B. Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease. Biochemical Pharmacology 2013, 86(2):200-209. http://www.ncbi.nlm.nih.gov/pubmed/23688501, 10.1016/j.bcp.2013.05.007.
102. Son Y., Kim S., Chung H.T., Pae H.O. Reactive oxygen species in the activation of MAP kinases. Methods in Enzymology 2013, 528:27-48. http://www.ncbi.nlm.nih.gov/pubmed/23849857, 10.1016/B978-0-12-405881-1.00002-1.
103. Theodosiou A., Ashworth A. MAP kinase phosphatases. Genome Biology 2002, 3(7). REVIEWS3009.1-REVIEWS3009.10. 10.1186/gb-2002-3-7-reviews3009.
104. Kamata H., Honda S., Maeda S., Chang L., Hirata H., Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005, 120(5):649-661. http://www.ncbi.nlm.nih.gov/pubmed/15766528, 10.1016/j.cell.2004.12.041.
105. Heneberg P., Dráber P. Regulation of cys-based protein tyrosine phosphatases via reactive oxygen and nitrogen species in mast cells and basophils. Current Medicinal Chemistry 2005, 12(16):1859-1871. http://www.ncbi.nlm.nih.gov/pubmed/16101506, 10.2174/0929867054546636.
106. Geraldes P., Hiraoka-Yamamoto J., Matsumoto M., Clermont A., Leitges M., Marette A., Aiello L.P., Kern T.S., King G.L. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nature Medicine 2009, 15(11):1298-1306. http://www.ncbi.nlm.nih.gov/pubmed/19881493, 10.1038/nm.2052.
107. Ryer E.J., Sakakibara K., Wang C., Sarkar D., Fisher P.B., Faries P.L., Kent K.C., Liu B. Protein kinase C delta induces apoptosis of vascular smooth muscle cells through induction of the tumor suppressor p53 by both p38-dependent and p38-independent mechanisms. Journal of Biological Chemistry 2005, 280(42):35310-35317. http://www.ncbi.nlm.nih.gov/pubmed/16118209, 10.1074/jbc.M507187200.
108. Gonzalez-Guerrico A.M., Kazanietz M.G. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. Journal of Biological Chemistry 2005, 280(47):38982-38991. http://www.ncbi.nlm.nih.gov/pubmed/16183650, 10.1074/jbc.M506767200.
109. Kwon J., Lee S.R., Yang K.S., Ahn Y., Kim Y.J., Stadtman E.R., Rhee S.G. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(47):16419-16424. http://www.ncbi.nlm.nih.gov/pubmed/15534200, 10.1073/pnas.0407396101.
110. Lee Y.J., Shukla S.D. Pro- and anti-apoptotic roles of c-Jun N-terminal kinase (JNK) in ethanol and acetaldehyde exposed rat hepatocytes. European Journal of Pharmacology 2005, 508(1-3):31-45. http://www.ncbi.nlm.nih.gov/pubmed/15680252, 10.1016/j.ejphar.2004.12.006.
111. Yang L., Wu D., Wang X., Cederbaum A.I. Cytochrome P4502E1, oxidative stress, JNK, and autophagy in acute alcohol-induced fatty liver. Free Radical Biology and Medicine 2012, 53(5):1170-1180. http://www.ncbi.nlm.nih.gov/pubmed/22749809, 10.1016/j.freeradbiomed.2012.06.029.
112. Bae M.A., Pie J.E., Song B.J. Acetaminophen induces apoptosis of C6 glioma cells by activating the c-Jun NH(2)-terminal protein kinase-related cell death pathway. Molecular Pharmacology 2001, 60(4):847-856. http://www.ncbi.nlm.nih.gov/pubmed/11562448.
113. Gunawan B.K., Liu Z.X., Han D., Hanawa N., Gaarde W.A., Kaplowitz N. C-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006, 131(1):165-178. http://www.ncbi.nlm.nih.gov/pubmed/16831600, 10.1053/j.gastro.2006.03.045.
114. Henderson N.C., Pollock K.J., Frew J., Mackinnon A.C., Flavell R.A., Davis R.J., Sethi T., Simpson K.J. Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure. Gut 2007, 56(7):982-990. http://www.ncbi.nlm.nih.gov/pubmed/17185352, 10.1136/gut.2006.104372.
115. Hanawa N., Shinohara M., Saberi B., Gaarde W.A., Han D., Kaplowitz N. Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. Journal of Biological Chemistry 2008, 283(20):13565-13577. http://www.ncbi.nlm.nih.gov/pubmed/18337250, 10.1074/jbc.M708916200.
116. Win S., Than T.A., Han D., Petrovic L.M., Kaplowitz N. C-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial sab protein expression in mice. Journal of Biological Chemistry 2011, 286(40):35071-35078. http://www.ncbi.nlm.nih.gov/pubmed/21844199, 10.1074/jbc.M111.276089.
117. Wu D., Cederbaum A.I. Role of p38 MAPK in CYP2E1-dependent arachidonic acid toxicity. Journal of Biological Chemistry 2003, 278(2):1115-1124. http://www.ncbi.nlm.nih.gov/pubmed/12403788, 10.1074/jbc.M207856200.
118. Soh Y., Jeong K.S., Lee I.J., Bae M.A., Kim Y.C., Song B.J. Selective activation of the c-Jun N-terminal protein kinase pathway during 4-hydroxynonenal-induced apoptosis of PC12 cells. Molecular Pharmacology 2000, 58(3):535-541. http://www.ncbi.nlm.nih.gov/pubmed/10953046.
119. Solinas G., Naugler W., Galimi F., Lee M.S., Karin M. Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(44):16454-16459. http://www.ncbi.nlm.nih.gov/pubmed/17050683, 10.1073/pnas.0607626103.
120. Bae M.A., Song B.J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Molecular Pharmacology 2003, 63(2):401-408. http://www.ncbi.nlm.nih.gov/pubmed/12527812, 10.1124/mol.63.2.401.
121. Schattenberg J.M., Wang Y., Singh R., Rigoli R.M., Czaja M.J. Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling. Journal of Biological Chemistry 2005, 280(11):9887-9894. http://www.ncbi.nlm.nih.gov/pubmed/15632182, 10.1074/jbc.M410310200.
122. Schattenberg J.M., Singh R., Wang Y., Lefkowitch J.H., Rigoli R.M., Scherer P.E., Czaja M.J. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology (Baltimore, Md.) 2006, 43(1):163-172. http://www.ncbi.nlm.nih.gov/pubmed/16374858, 10.1002/hep.20999.
123. Tuncman G., Hirosumi J., Solinas G., Chang L., Karin M., Hotamisligil G.S. Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(28):10741-10746. http://www.ncbi.nlm.nih.gov/pubmed/16818881, 10.1073/pnas.0603509103.
124. Gao Z., Zhang J., Kheterpal I., Kennedy N., Davis R.J., Ye J. Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity. Journal of Biological Chemistry 2011, 286(25):22227-22234. http://www.ncbi.nlm.nih.gov/pubmed/21540183, 10.1074/jbc.M111.228874.
125. Uehara T., Bennett B., Sakata S.T., Satoh Y., Bilter G.K., Westwick J.K., Brenner D.A. JNK mediates hepatic ischemia reperfusion injury. Journal of Hepatology 2005, 42(6):850-859. http://www.ncbi.nlm.nih.gov/pubmed/15885356, 10.1016/j.jhep.2005.01.030.
126. Seki E., Brenner D.A., Karin M. A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches. Gastroenterology 2012, 143(2):307-320. http://www.ncbi.nlm.nih.gov/pubmed/22705006, 10.1053/j.gastro.2012.06.004.
127. Wang X., Wu D., Yang L., Cederbaum A.I. Hepatotoxicity mediated by pyrazole (cytochrome P450 2E1) plus tumor necrosis factor alpha treatment occurs in c-Jun N-terminal kinase 2-/- but not in c-Jun N-terminal kinase 1-/- mice. Hepatology (Baltimore, Md.) 2011, 54(5):1753-1766. http://www.ncbi.nlm.nih.gov/pubmed/21748763, 10.1002/hep.24540.
128. Son Y., Cheong Y.K., Kim N.H., Chung H.T., Kang D.G., Pae H.O. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?. Journal of Signal Transduction 2011, 2011:792639. http://www.ncbi.nlm.nih.gov/pubmed/21637379, 10.1155/2011/792639.
129. Kim B.J., Ryu S.W., Song B.J. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. Journal of Biological Chemistry 2006, 281(30):21256-21265. http://www.ncbi.nlm.nih.gov/pubmed/16709574, 10.1074/jbc.M510644200.
130. Kharbanda S., Saxena S., Yoshida K., Pandey P., Kaneki M., Wang Q., Cheng K., Chen Y.N., Campbell A., Sudha T. Translocation of SAPK/JNK to mitochondria and interaction with Bcl-x(L) in response to DNA damage. Journal of Biological Chemistry 2000, 275(1):322-327. http://www.ncbi.nlm.nih.gov/pubmed/10617621.
131. Xie Y., McGill M.R., Dorko K., Kumer S.C., Schmitt T.M., Forster J., Jaeschke H. Mechanisms of acetaminophen-induced cell death in primary human hepatocytes. Toxicology and Applied Pharmacology 2014, 279(3):266-274. http://www.ncbi.nlm.nih.gov/pubmed/24905542, 10.1016/j.taap.2014.05.010.
132. Ferramosca A., Zara V. Biogenesis of mitochondrial carrier proteins: molecular mechanisms of import into mitochondria. Biochimica et Biophysica Acta 2013, 1833(3):494-502. http://www.ncbi.nlm.nih.gov/pubmed/23201437, 10.1016/j.bbamcr.2012.11.014.
133. Moon K.H., Lee Y.M., Song B.J. Inhibition of hepatic mitochondrial aldehyde dehydrogenase by carbon tetrachloride through JNK-mediated phosphorylation. Free Radical Biology and Medicine 2010, 48(3):391-398. http://www.ncbi.nlm.nih.gov/pubmed/19922789, 10.1016/j.freeradbiomed.2009.11.008.
134. Win S., Than T.A., Fernandez-Checa J.C., Kaplowitz N. JNK interaction with sab mediates ER stress induced inhibition of mitochondrial respiration and cell death. Cell Death and Disease 2014, 5:e989. http://www.ncbi.nlm.nih.gov/pubmed/24407242, 10.1038/cddis.2013.522.
135. Schroeter H., Boyd C.S., Ahmed R., Spencer J.P.E., Duncan R.F., Rice-Evans C., Cadenas E. C-Jun N-terminal kinase (JNK)-mediated modulation of brain mitochondria function: new target proteins for JNK signalling in mitochondrion-dependent apoptosis. Biochemical Journal 2003, 372(2):359-369. http://www.ncbi.nlm.nih.gov/pubmed/12614194, 10.1042/BJ20030201.
136. Hardie D.G. AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels. Annual Review of Nutrition 2014, 34:31-55. http://www.ncbi.nlm.nih.gov/pubmed/24850385, 10.1146/annurev-nutr-071812-161148.
137. You M., Matsumoto M., Pacold C.M., Cho W.K., Crabb D.W. The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology 2004, 127(6):1798-1808. http://www.ncbi.nlm.nih.gov/pubmed/15578517, 10.1053/j.gastro.2004.09.049.
138. Singhal S.S., Figarola J., Singhal J., Reddy M.A., Liu X., Berz D., Natarajan R., Awasthi S. RLIP76 protein knockdown attenuates obesity due to a high-fat diet. Journal of Biological Chemistry 2013, 288(32):23394-23406. http://www.ncbi.nlm.nih.gov/pubmed/23821548, 10.1074/jbc.M113.480194.
139. Saberi B., Ybanez M.D., Johnson H.S., Gaarde W.A., Han D., Kaplowitz N. Protein kinase C (PKC) participates in acetaminophen hepatotoxicity through c-jun-N-terminal kinase (JNK)-dependent and -independent signaling pathways. Hepatology (Baltimore, Md.) 2014, 59(4):1543-1554. http://www.ncbi.nlm.nih.gov/pubmed/23873604, 10.1002/hep.26625.
140. Sun Z., Feng D., Everett L.J., Bugge A., Lazar M.A. Circadian epigenomic remodeling and hepatic lipogenesis: lessons from HDAC3. Cold Spring Harbor Symposia on Quantitative Biology 2011, 76:49-55. http://www.ncbi.nlm.nih.gov/pubmed/21900149, 10.1101/sqb.2011.76.011494.
141. Kim S.C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N.V., White M., Yang X.J., Zhao Y. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Molecular Cell 2006, 23(4):607-618. http://www.ncbi.nlm.nih.gov/pubmed/16916647, 10.1016/j.molcel.2006.06.026.
142. You M., Liang X., Ajmo J.M., Ness G.C. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. American Journal of Physiology: Gastrointestinal and Liver Physiology 2008, 294(4):G892-G898. http://www.ncbi.nlm.nih.gov/pubmed/18239056, 10.1152/ajpgi.00575.2007.
143. Lieber C.S., Leo M.A., Wang X., Decarli L.M. Effect of chronic alcohol consumption on hepatic SIRT1 and PGC-1alpha in rats. Biochemical and Biophysical Research Communications 2008, 370(1):44-48. http://www.ncbi.nlm.nih.gov/pubmed/18342626, 10.1016/j.bbrc.2008.03.005.
144. Picklo M.J.Sr Ethanol intoxication increases hepatic N-lysyl protein acetylation. Biochemical and Biophysical Research Communications 2008, 376(3):615-619. http://www.ncbi.nlm.nih.gov/pubmed/18804449, 10.1016/j.bbrc.2008.09.039.
145. Shepard B.D., Tuma D.J., Tuma P.L. Chronic ethanol consumption induces global hepatic protein hyperacetylation. Alcoholism, Clinical and Experimental Research 2010, 34(2):280-291. http://www.ncbi.nlm.nih.gov/pubmed/19951295, 10.1111/j.1530-0277.2009.01091.x.
146. Kendrick A.A., Choudhury M., Rahman S.M., McCurdy C.E., Friederich M., Van Hove J.L., Watson P.A., Birdsey N., Bao J., Gius D., Sack M.N., Jing E., Kahn C.R., Friedman J.E., Jonscher K.R. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochemical Journal 2011, 433(3):505-514. http://www.ncbi.nlm.nih.gov/pubmed/21044047, 10.1042/BJ20100791.
147. Hirschey M.D., Shimazu T., Jing E., Grueter C.A., Collins A.M., Aouizerat B., Stančáková A., Goetzman E., Lam M.M., Schwer B., Stevens R.D., Muehlbauer M.J., Kakar S., Bass N.M., Kuusisto J., Laakso M., Alt F.W., Newgard C.B., Farese R.V., Kahn C.R., Verdin E. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Molecular Cell 2011, 44(2):177-190. http://www.ncbi.nlm.nih.gov/pubmed/21856199, 10.1016/j.molcel.2011.07.019.
148. Valdecantos M.P., Pérez-Matute P., González-Muniesa P., Prieto-Hontoria P.L., Moreno-Aliaga M.J., Martínez J.A. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity (Silver Spring, Md.) 2012, 20(10):1974-1983. http://www.ncbi.nlm.nih.gov/pubmed/22327056, 10.1038/oby.2012.32.
149. Lieber C.S., Leo M.A., Wang X., Decarli L.M. Alcohol alters hepatic FoxO1, p53, and mitochondrial SIRT5 deacetylation function. Biochemical and Biophysical Research Communications 2008, 373(2):246-252. http://www.ncbi.nlm.nih.gov/pubmed/18555008, 10.1016/j.bbrc.2008.06.006.
150. Shulga N., Pastorino J.G. Ethanol sensitizes mitochondria to the permeability transition by inhibiting deacetylation of cyclophilin-D mediated by sirtuin-3. Journal of Cell Science 2010, 123(23):4117-4127. http://www.ncbi.nlm.nih.gov/pubmed/21062897, 10.1242/jcs.073502.
151. Fritz K.S., Galligan J.J., Smathers R.L., Roede J.R., Shearn C.T., Reigan P., Petersen D.R. 4-hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chemical Research in Toxicology 2011, 24(5):651-662. http://www.ncbi.nlm.nih.gov/pubmed/21449565, 10.1021/tx100355a.
152. Fritz K.S., Galligan J.J., Hirschey M.D., Verdin E., Petersen D.R. Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice. Journal of Proteome Research 2012, 11(3):1633-1643. http://www.ncbi.nlm.nih.gov/pubmed/22309199, 10.1021/pr2008384.
153. Fritz K.S., Green M.F., Petersen D.R., Hirschey M.D. Ethanol metabolism modifies hepatic protein acylation in mice. PloS One 2013, 8(9):e75868. http://www.ncbi.nlm.nih.gov/pubmed/24073283, 10.1371/journal.pone.0075868.
154. Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., Grueter C.A., Harris C., Biddinger S., Ilkayeva O.R., Stevens R.D., Li Y., Saha A.K., Ruderman N.B., Bain J.R., Newgard C.B., Farese R.V., Alt F.W., Kahn C.R., Verdin E. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464(7285):121-125. http://www.ncbi.nlm.nih.gov/pubmed/20203611, 10.1038/nature08778.
155. Hirschey M.D., Shimazu T., Huang J.Y., Schwer B., Verdin E. SIRT3 regulates mitochondrial protein acetylation and intermediary metabolism. Cold Spring Harbor Symposia on Quantitative Biology 2011, 76:267-277. http://www.ncbi.nlm.nih.gov/pubmed/22114326, 10.1101/sqb.2011.76.010850.
156. Yang S.J., Lim Y. Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation. Metabolism: Clinical and Experimental 2014, 63(5):693-701. http://www.ncbi.nlm.nih.gov/pubmed/24629563, 10.1016/j.metabol.2014.02.003.
157. Wang S., Moustaid-Moussa N., Chen L., Mo H., Shastri A., Su R., Bapat P., Kwun I., Shen C.L. Novel insights of dietary polyphenols and obesity. Journal of Nutritional Biochemistry 2014, 25(1):1-18. http://www.ncbi.nlm.nih.gov/pubmed/24314860, 10.1016/j.jnutbio.2013.09.001.
158. Still A.J., Floyd B.J., Hebert A.S., Bingman C.A., Carson J.J., Gunderson D.R., Dolan B.K., Grimsrud P.A., Dittenhafer-Reed K.E., Stapleton D.S., Keller M.P., Westphall M.S., Denu J.M., Attie A.D., Coon J.J., Pagliarini D.J. Quantification of mitochondrial acetylation dynamics highlights prominent sites of metabolic regulation. Journal of Biological Chemistry 2013, 288(36):26209-26219. http://www.ncbi.nlm.nih.gov/pubmed/23864654, 10.1074/jbc.M113.483396.
159. Paik W.K., Pearson D., Lee H.W., Kim S. Nonenzymatic acetylation of histones with acetyl-CoA. Biochimica et Biophysica Acta 1970, 213(2):513-522. http://www.ncbi.nlm.nih.gov/pubmed/5534125, 10.1016/0005-2787(70)90058-4.
160. Ramponi G., Manao G., Camici G. Nonenzymatic acetylation of histones with acetyl phosphate and acetyl adenylate. Biochemistry 1975, 14(12):2681-2685. http://www.ncbi.nlm.nih.gov/pubmed/238571, 10.1021/bi00683a018.
161. Tanner K.G., Trievel R.C., Kuo M.H., Howard R.M., Berger S.L., Allis C.D., Marmorstein R., Denu J.M. Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator. Journal of Biological Chemistry 1999, 274(26):18157-18160. http://www.ncbi.nlm.nih.gov/pubmed/10373413, 10.1074/jbc.274.26.18157.
162. French S.W., Wong K., Jui L., Albano E., Hagbjork A.L., Ingelman-Sundberg M. Effect of ethanol on cytochrome P450 2E1 (CYP2E1), lipid peroxidation, and serum protein adduct formation in relation to liver pathology pathogenesis. Experimental and Molecular Pathology 1993, 58(1):61-75. http://www.ncbi.nlm.nih.gov/pubmed/8454037, 10.1006/exmp.1993.1006.
163. Niemelä O., Parkkila S., Pasanen M., Iimuro Y., Bradford B., Thurman R.G. Early alcoholic liver injury: formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of CYP2E1 and CYP3A. Alcoholism, Clinical and Experimental Research 1998, 22:2118-2124. http://www.ncbi.nlm.nih.gov/pubmed/9884160, 10.1111/j.1530-0277.1998.tb05925.x.
164. Brooks P.J., Enoch M.A., Goldman D., Li T.K., Yokoyama A. The alcohol flushing response: an unrecognized risk factor for esophageal cancer from alcohol consumption. PLoS Medicine 2009, 6(3):e50. http://www.ncbi.nlm.nih.gov/pubmed/19320537, 10.1371/journal.pmed.1000050.
165. Yokoyama A., Muramatsu T., Omori T., Yokoyama T., Matsushita S., Higuchi S., Maruyama K., Ishii H. Alcohol and aldehyde dehydrogenase gene polymorphisms and oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcinogenesis 2001, 22(3):433-439. http://www.ncbi.nlm.nih.gov/pubmed/11238183, 10.1093/carcin/22.3.433.
166. Jaeschke H., Gores G.J., Cederbaum A.I., Hinson J.A., Pessayre D., Lemasters J.J. Mechanisms of hepatotoxicity. Toxicological Sciences: an Official Journal of the Society of Toxicology 2002, 65(2):166-176. http://www.ncbi.nlm.nih.gov/pubmed/11812920, 10.1093/toxsci/65.2.166.
167. Galligan J.J., Smathers R.L., Fritz K.S., Epperson L.E., Hunter L.E., Petersen D.R. Protein carbonylation in a murine model for early alcoholic liver disease. Chemical Research in Toxicology 2012, 25(5):1012-1021. http://www.ncbi.nlm.nih.gov/pubmed/22502949, 10.1021/tx300002q.
168. Fritz K.S., Petersen D.R. An overview of the chemistry and biology of reactive aldehydes. Free Radical Biology and Medicine 2013, 59:85-91. http://www.ncbi.nlm.nih.gov/pubmed/22750507, 10.1016/j.freeradbiomed.2012.06.025.
169. Cohn J.A., Tsai L., Friguet B., Szweda L.I. Chemical characterization of a protein-4-hydroxy-2-nonenal cross-link: immunochemical detection in mitochondria exposed to oxidative stress. Archives of Biochemistry and Biophysics 1996, 328(1):158-164. http://www.ncbi.nlm.nih.gov/pubmed/8638925, 10.1006/abbi.1996.0156.
170. Niemelä O., Parkkila S., Ylä-Herttuala S., Villanueva J., Ruebner B., Halsted C.H. Sequential acetaldehyde production, lipid peroxidation, and fibrogenesis in micropig model of alcohol-induced liver disease. Hepatology (Baltimore, Md.) 1995, 22(4 Pt 1):1208-1214. http://www.ncbi.nlm.nih.gov/pubmed/7557872, 10.1002/hep.1840220428.
171. Li C.J., Nanji A.A., Siakotos A.N., Lin R.C. Acetaldehyde-modified and 4-hydroxynonenal-modified proteins in the livers of rats with alcoholic liver disease. Hepatology (Baltimore, Md.) 1997, 26(3):650-657. http://www.ncbi.nlm.nih.gov/pubmed/9303495, 10.1002/hep.510260317.
172. Chen J., Robinson N.C., Schenker S., Frosto T.A., Henderson G.I. Formation of 4-hydroxynonenal adducts with cytochrome c oxidase in rats following short-term ethanol intake. Hepatology (Baltimore, Md.) 1999, 29(6):1792-1798. http://www.ncbi.nlm.nih.gov/pubmed/10347122, 10.1002/hep.510290611.
173. Doorn J.A., Hurley T.D., Petersen D.R. Inhibition of human mitochondrial aldehyde dehydrogenase by 4-hydroxynon-2-enal and 4-oxonon-2-enal. Chemical Research in Toxicology 2006, 19(1):102-110. http://www.ncbi.nlm.nih.gov/pubmed/16411662, 10.1021/tx0501839.
174. Carbone D.L., Doorn J.A., Kiebler Z., Petersen D.R. Cysteine modification by lipid peroxidation products inhibits protein disulfide isomerase. Chemical Research in Toxicology 2005, 18(8):1324-1331. http://www.ncbi.nlm.nih.gov/pubmed/16097806, 10.1021/tx050078z.
175. Galligan J.J., Fritz K.S., Backos D.S., Shearn C.T., Smathers R.L., Jiang H., MacLean K.N., Reigan P.R., Petersen D.R. Oxidative stress-mediated aldehyde adduction of GRP78 in a mouse model of alcoholic liver disease: functional independence of ATPase activity and chaperone function. Free Radical Biology and Medicine 2014, 73:411-420. http://www.ncbi.nlm.nih.gov/pubmed/24924946, 10.1016/j.freeradbiomed.2014.06.002.
176. Backos D.S., Fritz K.S., Roede J.R., Petersen D.R., Franklin C.C. Posttranslational modification and regulation of glutamate-cysteine ligase by the α,β-unsaturated aldehyde 4-hydroxy-2-nonenal. Free Radical Biology and Medicine 2011, 50(1):14-26. http://www.ncbi.nlm.nih.gov/pubmed/20970495, 10.1016/j.freeradbiomed.2010.10.694.
177. Sampey B.P., Stewart B.J., Petersen D.R. Ethanol-induced modulation of hepatocellular extracellular signal-regulated kinase-1/2 activity via 4-hydroxynonenal. Journal of Biological Chemistry 2007, 282(3):1925-1937. http://www.ncbi.nlm.nih.gov/pubmed/17107949, 10.1074/jbc.M610602200.
178. Shearn C.T., Smathers R.L., Backos D.S., Reigan P., Orlicky D.J., Petersen D.R. Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Free Radical Biology and Medicine 2013, 65:680-692. http://www.ncbi.nlm.nih.gov/pubmed/23872024, 10.1016/j.freeradbiomed.2013.07.011.
179. Shearn C.T., Backos D.S., Orlicky D.J., Smathers-McCullough R.L., Petersen D.R. Identification of 5' AMP-activated kinase as a target of reactive aldehydes during chronic ingestion of high concentrations of ethanol. Journal of Biological Chemistry 2014, 289(22):15449-15462. http://www.ncbi.nlm.nih.gov/pubmed/24722988, 10.1074/jbc.M113.543942.
180. Mottaran E., Stewart S.F., Rolla R., Vay D., Cipriani V., Moretti M., Vidali M., Sartori M., Rigamonti C., Day C.P., Albano E. Lipid peroxidation contributes to immune reactions associated with alcoholic liver disease. Free Radical Biology and Medicine 2002, 32(1):38-45. http://www.ncbi.nlm.nih.gov/pubmed/11755315, 10.1016/S0891-5849(01)00757-2.
181. Jeong K.S., Soh Y., Jeng J., Felder M.R., Hardwick J.P., Song B.J. Cytochrome P450 2E1 (CYP2E1)-dependent production of a 37-kDa acetaldehyde-protein adduct in the rat liver. Archives of Biochemistry and Biophysics 2000, 384(1):81-87. http://www.ncbi.nlm.nih.gov/pubmed/11147839, 10.1006/abbi.2000.2119.
182. Bardag-Gorce F., Li J., French B.A., French S.W. The effect of ethanol-induced CYP2E1 on proteasome activity: the role of 4-hydroxynonenal. Experimental and Molecular Pathology 2005, 78(2):109-115. http://www.ncbi.nlm.nih.gov/pubmed/15713435, 10.1016/j.yexmp.2004.10.005.
183. Chen J., Henderson G.I., Freeman G.L. Role of 4-hydroxynonenal in modification of cytochrome c oxidase in ischemia/reperfused rat heart. Journal of Molecular and Cellular Cardiology 2001, 33(11):1919-1927. http://www.ncbi.nlm.nih.gov/pubmed/11708837, 10.1006/jmcc.2001.1454.
184. Chavez J.D., Wu J., Bisson W., Maier C.S. Site-specific proteomic analysis of lipoxidation adducts in cardiac mitochondria reveals chemical diversity of 2-alkenal adduction. Journal of Proteomics 2011, 74(11):2417-2429. http://www.ncbi.nlm.nih.gov/pubmed/21513823, 10.1016/j.jprot.2011.03.031.
185. Abdelmegeed M.A., Banerjee A., Yoo S.H., Jang S.H., Gonzalez F.J., Song B.J. Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. Journal of Hepatology 2012, 57(4):860-866. http://www.ncbi.nlm.nih.gov/pubmed/22668639, 10.1016/j.jhep.2012.05.019.
186. Mali V.R., Ning R., Chen J., Yang X.P., Xu J., Palaniyandi S.S. Impairment of aldehyde dehydrogenase-2 by 4-hydroxy-2-nonenal adduct formation and cardiomyocyte hypertrophy in mice fed a high-fat diet and injected with low-dose streptozotocin. Experimental Biology and Medicine (Maywood, N.J.) 2014, 239(5):610-618. http://www.ncbi.nlm.nih.gov/pubmed/24651616, 10.1177/1535370213520109.
187. Chen C.-H., Budas G.R., Churchill E.N., Disatnik M.-H., Hurley T.D., Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science (New York, N.Y.) 2008, 321(5895):1493-1495. http://www.ncbi.nlm.nih.gov/pubmed/18787169, 10.1126/science.1158554.
188. Doser T.A., Turdi S., Thomas D.P., Epstein P.N., Li S.Y., Ren J. Transgenic overexpression of aldehyde dehydrogenase-2 rescues chronic alcohol intake-induced myocardial hypertrophy and contractile dysfunction. Circulation 2009, 119(14):1941-1949. http://www.ncbi.nlm.nih.gov/pubmed/19332462, 10.1161/CIRCULATIONAHA.108.823799.
189. Zhang Y., Mi S.L., Hu N., Doser T.A., Sun A., Ge J., Ren J. Mitochondrial aldehyde dehydrogenase 2 accentuates aging-induced cardiac remodeling and contractile dysfunction: role of AMPK, Sirt1, and mitochondrial function. Free Radical Biology and Medicine 2014, 71:208-220. http://www.ncbi.nlm.nih.gov/pubmed/24675227, 10.1016/j.freeradbiomed.2014.03.018.
190. Daffu G., del Pozo C.H., O'Shea K.M., Ananthakrishnan R., Ramasamy R., Schmidt A.M. Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. International Journal of Molecular Sciences 2013, 14(10):19891-19910. http://www.ncbi.nlm.nih.gov/pubmed/24084731, 10.3390/ijms141019891.
191. Ott C., Jacobs K., Haucke E., Navarrete Santos A., Grune T., Simm A. Role of advanced glycation end products in cellular signaling. Redox Biology 2014, 2:411-429. http://www.ncbi.nlm.nih.gov/pubmed/24624331, 10.1016/j.redox.2013.12.016.
192. Niforou K., Cheimonidou C., Trougakos I.P. Molecular chaperones and proteostasis regulation during redox imbalance. Redox Biology 2014, 2:323-332. http://www.ncbi.nlm.nih.gov/pubmed/24563850, 10.1016/j.redox.2014.01.017.
193. Hayashi N., George J., Takeuchi M., Fukumura A., Toshikuni N., Arisawa T., Tsutsumi M. Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease. PloS One 2013, 8(7):e70034. http://www.ncbi.nlm.nih.gov/pubmed/23922897, 10.1371/journal.pone.0070034.
194. Ahmed N., Lüthen R., Häussinger D., Sebeková K., Schinzel R., Voelker W., Heidland A., Thornalley P.J. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. Annals of the New York Academy of Sciences 2005, 1043:718-724. http://www.ncbi.nlm.nih.gov/pubmed/16037298, 10.1196/annals.1333.083.
195. Baba S.P., Hellmann J., Srivastava S., Bhatnagar A. Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE). Chemico-Biological Interactions 2011, 191(1-3):357-363. 10.1016/j.cbi.2011.01.024.
196. Jiang J.X., Chen X., Fukada H., Serizawa N., Devaraj S., Török N.J. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice. Hepatology (Baltimore, Md.) 2013, 58(4):1339-1348. http://www.ncbi.nlm.nih.gov/pubmed/23703665, 10.1002/hep.26491.
197. Bakala H., Ladouce R., Baraibar M.A., Friguet B. Differential expression and glycative damage affect specific mitochondrial proteins with aging in rat liver. Biochimica et Biophysica Acta 2013, 1832(12):2057-2067. http://www.ncbi.nlm.nih.gov/pubmed/23906978, 10.1016/j.bbadis.2013.07.015.
198. Takeuchi M., Saito T. Cytotoxicity of acetaldehyde-derived advanced glycation end-products (AA-AGE) in alcoholic-induced neuronal degeneration. Alcoholism, Clinical and Experimental Research 2005, 29(12 Suppl):220S-224S. http://www.ncbi.nlm.nih.gov/pubmed/16385226, 10.1097/01.alc.0000190657.97988.c7.
199. Byun K., Bayarsaikhan D., Bayarsaikhan E., Son M., Oh S., Lee J., Son H.I., Won M.H., Kim S.U., Song B.J., Lee B. Microglial AGE-albumin is critical in promoting alcohol-induced neurodegeneration in Rats and humans. PloS One 2014, 9(8):e104699. http://www.ncbi.nlm.nih.gov/pubmed/25140518, 10.1371/journal.pone.0104699.
200. Vetreno R.P., Qin L., Crews F.T. Increased receptor for advanced glycation end product expression in the human alcoholic prefrontal cortex is linked to adolescent drinking. Neurobiology of Disease 2013, 59:52-62. http://www.ncbi.nlm.nih.gov/pubmed/23867237, 10.1016/j.nbd.2013.07.002.
201. Ahn S.M., Byun K., Cho K., Kim J.Y., Yoo J.S., Kim D., Paek S.H., Kim S.U., Simpson R.J., Lee B. Human microglial cells synthesize albumin in brain. PloS One 2008, 3(7):e2829. http://www.ncbi.nlm.nih.gov/pubmed/18665237, 10.1371/journal.pone.0002829.
202. Byun K., Bayarsaikhan E., Kim D., Kim C.Y., Mook-Jung I., Paek S.H., Kim S.U., Yamamoto T., Won M.H., Song B.J., Park Y.M., Lee B. Induction of neuronal death by microglial AGE-albumin: implications for Alzheimer's disease. PloS One 2012, 7(5):e37917. http://www.ncbi.nlm.nih.gov/pubmed/22662249, 10.1371/journal.pone.0037917.
203. Albano E., Clot P., Morimoto M., Tomasi A., Ingelman-Sundberg M., French S.W. Role of cytochrome P4502E1-dependent formation of hydroxyethyl free radical in the development of liver damage in rats intragastrically fed with ethanol. Hepatology (Baltimore, Md.) 1996, 23(1):155-163. http://www.ncbi.nlm.nih.gov/pubmed/8550035, 10.1002/hep.510230121.
204. Clot P., Albano E., Eliasson E., Tabone M., Aricò S., Israel Y., Moncada C., Ingelman-Sundberg M. Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology 1996, 111(1):206-216. http://www.ncbi.nlm.nih.gov/pubmed/8698201, 10.1053/gast.1996.v111.pm8698201.
205. Cheshchevik V.T., Lapshina E.A., Dremza I.K., Zabrodskaya S.V., Reiter R.J., Prokopchik N.I., Zavodnik I.B. Rat liver mitochondrial damage under acute or chronic carbon tetrachloride-induced intoxication: protection by melatonin and cranberry flavonoids. Toxicology and Applied Pharmacology 2012, 261(3):271-279. http://www.ncbi.nlm.nih.gov/pubmed/22521486, 10.1016/j.taap.2012.04.007.
206. Kim H.S., Quon M.J., Kim J.A. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biology 2014, 2:187-195. http://www.ncbi.nlm.nih.gov/pubmed/24494192, 10.1016/j.redox.2013.12.022.
207. Zou X., Yan C., Shi Y., Cao K., Xu J., Wang X., Chen C., Luo C., Li Y., Gao J., Pang W., Zhao J., Zhao F., Li H., Zheng A., Sun W., Long J., Szeto I.M., Zhao Y., Dong Z., Zhang P., Wang J., Lu W., Zhang Y., Liu J., Feng Z. Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. Antioxidants and Redox Signaling 2014, http://www.ncbi.nlm.nih.gov/pubmed/24393106, 10.1089/ars.2013.5538.
208. Pallauf K., Giller K., Huebbe P., Rimbach G. Nutrition and healthy ageing: calorie restriction or polyphenol-rich "MediterrAsian" diet?. Oxidative Medicine and Cellular Longevity 2013, 2013:707421. http://www.ncbi.nlm.nih.gov/pubmed/24069505, 10.1155/2013/707421.
209. Davinelli S., Sapere N., Zella D., Bracale R., Intrieri M., Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxidative Medicine and Cellular Longevity 2012, 2012:386527. http://www.ncbi.nlm.nih.gov/pubmed/22690271, 10.1155/2012/386527.
210. Basli A., Soulet S., Chaher N., Mérillon J.M., Chibane M., Monti J.P., Richard T. Wine polyphenols: potential agents in neuroprotection, oxid. Medicine 2012, 2012:805762.
211. Rodrigues C.F., Ascenção K., Silva F.A., Sarmento B., Oliveira M.B., Andrade J.C. Drug-delivery systems of green tea catechins for improved stability and bioavailability. Current Medicinal Chemistry 2013, 20(37):4744-4757. http://www.ncbi.nlm.nih.gov/pubmed/23834175, 10.2174/09298673113209990158.
212. Bailey S.M., Robinson G., Pinner A., Chamlee L., Ulasova E., Pompilius M., Page G.P., Chhieng D., Jhala N., Landar A., Kharbanda K.K., Ballinger S., Darley-Usmar V. S-adenosylmethionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver. American Journal of Physiology: Gastrointestinal and Liver Physiology 2006, 291(5):G857-G867. http://www.ncbi.nlm.nih.gov/pubmed/16825707, 10.1152/ajpgi.00044.2006.
213. Andringa K.K., King A.L., Eccleston H.B., Mantena S.K., Landar A., Jhala N.C., Dickinson D.A., Squadrito G.L., Bailey S.M. Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection. American Journal of Physiology: Gastrointestinal and Liver Physiology 2010, 298(5):G732-G745. http://www.ncbi.nlm.nih.gov/pubmed/20150243, 10.1152/ajpgi.00332.2009.
214. Kharbanda K.K., Todero S.L., King A.L., Osna N.A., McVicker B.L., Tuma D.J., Wisecarver J.L., Bailey S.M. Betaine treatment attenuates chronic ethanol-induced hepatic steatosis and alterations to the mitochondrial respiratory chain proteome. International Journal of Hepatology 2012, 2012:962183. http://www.ncbi.nlm.nih.gov/pubmed/22187660, 10.1155/2012/962183.
215. Santamaria E., Avila M.A., Latasa M.U., Rubio A., Martin-Duce A., Lu S.C., Mato J.M., Corrales F.J. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(6):3065-3070. http://www.ncbi.nlm.nih.gov/pubmed/12631701, 10.1073/pnas.0536625100.
216. Caballero F., Fernández A., Matías N., Martínez L., Fucho R., Elena M., Caballeria J., Morales A., Fernández-Checa J.C., García-Ruiz C. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-l-methionine and glutathione. Journal of Biological Chemistry 2010, 285(24):18528-18536. http://www.ncbi.nlm.nih.gov/pubmed/20395294, 10.1074/jbc.M109.099333.
217. Basaranoglu M., Basaranoglu G., Sentürk H. From fatty liver to fibrosis: a tale of "second hit". World Journal of Gastroenterology: WJG 2013, 19(8):1158-1165. http://www.ncbi.nlm.nih.gov/pubmed/23483818, 10.3748/wjg.v19.i8.1158.
218. Zhao K., Zhao G.M., Wu D., Soong Y., Birk A.V., Schiller P.W., Szeto H.H. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry 2004, 279(33):34682-34690. http://www.ncbi.nlm.nih.gov/pubmed/15178689, 10.1074/jbc.M402999200.
219. Sheu S.S., Nauduri D., Anders M.W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochimica et Biophysica Acta 2006, 1762(2):256-265. http://www.ncbi.nlm.nih.gov/pubmed/16352423, 10.1016/j.bbadis.2005.10.007.
220. Szeto H.H. Cell-permeable, mitochondrial-targeted, peptide antioxidants. AAPS Journal 2006, 8(2):E277-E283. http://www.ncbi.nlm.nih.gov/pubmed/16796378, 10.1208/aapsj080232.
221. Melov S., Doctrow S.R., Schneider J.A., Haberson J., Patel M., Coskun P.E., Huffman K., Wallace D.C., Malfroy B. Lifespan extension and rescue of spongiform encephalopathy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. Journal of Neuroscience 2001, 21(21):8348-8353. http://www.ncbi.nlm.nih.gov/pubmed/11606622.
222. Reily C., Mitchell T., Chacko B.K., Benavides G., Murphy M.P., Darley-Usmar V. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biology 2013, 1(1):86-93. http://www.ncbi.nlm.nih.gov/pubmed/23667828, 10.1016/j.redox.2012.11.009.
223. Murphy M.P. Antioxidants as therapies: can we improve on nature?. Free Radical Biology and Medicine 2014, 66:20-23. http://www.ncbi.nlm.nih.gov/pubmed/23603661, 10.1016/j.freeradbiomed.2013.04.010.
224. Jauslin M.L., Meier T., Smith R.A., Murphy M.P. Mitochondria-targeted antioxidants protect Friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2003, 17(13):1972-1974. http://www.ncbi.nlm.nih.gov/pubmed/12923074, 10.1096/fj.03-0240fje.
225. -(AkitaJ) mice by the mitochondria-targeted therapy MitoQ. Biochemical Journal 2010, 432(1):9-19. http://www.ncbi.nlm.nih.gov/pubmed/20825366, 10.1042/BJ20100308.
226. Mukhopadhyay P., Horváth B., Zsengellér Z., Zielonka J., Tanchian G., Holovac E., Kechrid M., Patel V., Stillman I.E., Parikh S.M., Joseph J., Kalyanaraman B., Pacher P. Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy. Free Radical Biology and Medicine 2012, 52(2):497-506. http://www.ncbi.nlm.nih.gov/pubmed/22120494, 10.1016/j.freeradbiomed.2011.11.001.
227. Vergeade A., Mulder P., Vendeville-Dehaudt C., Estour F., Fortin D., Ventura-Clapier R., Thuillez C., Monteil C. Mitochondrial impairment contributes to cocaine-induced cardiac dysfunction: prevention by the targeted antioxidant MitoQ. Free Radical Biology and Medicine 2010, 49(5):748-756. http://www.ncbi.nlm.nih.gov/pubmed/20566328, 10.1016/j.freeradbiomed.2010.05.024.
228. Mukhopadhyay P., Horváth B., Zsengeller Z., Bátkai S., Cao Z., Kechrid M., Holovac E., Erdelyi K., Tanchian G., Liaudet L., Stillman I.E., Joseph J., Kalyanaraman B., Pacher P. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants. Free Radical Biology and Medicine 2012, 53(5):1123-1138. http://www.ncbi.nlm.nih.gov/pubmed/22683818, 10.1016/j.freeradbiomed.2012.05.036.
229. Chacko B.K., Srivastava A., Johnson M.S., Benavides G.A., Chang M.J., Ye Y., Jhala N., Murphy M.P., Kalyanaraman B., Darley-Usmar V.M. Mitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis. Hepatology (Baltimore, Md.) 2011, 54(1):153-163. http://www.ncbi.nlm.nih.gov/pubmed/21520201, 10.1002/hep.24377.
230. Gane E.J., Weilert F., Orr D.W., Keogh G.F., Gibson M., Lockhart M.M., Frampton C.M., Taylor K.M., Smith R.A., Murphy M.P. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver International: Official Journal of the International Association for the Study of the Liver 2010, 30(7):1019-1026. http://www.ncbi.nlm.nih.gov/pubmed/20492507, 10.1111/j.1478-3231.2010.02250.x.
231. Smith R.A., Murphy M.P. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Annals of the New York Academy of Sciences 2010, 1201:96-103. http://www.ncbi.nlm.nih.gov/pubmed/20649545, 10.1111/j.1749-6632.2010.05627.x.
232. Zhong W., McClain C.J., Cave M., Kang Y.J., Zhou Z. The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. American Journal of Physiology. Gastrointestinal and Liver Physiology 2010, 298(5):G625-G633. http://www.ncbi.nlm.nih.gov/pubmed/20167873, 10.1152/ajpgi.00350.2009.
233. Kirpich I.A., Feng W., Wang Y., Liu Y., Barker D.F., Barve S.S., McClain C.J. The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic Toll-like receptor expression in a mouse model of alcoholic liver disease. Alcoholism, Clinical and Experimental Research 2012, 36(5):835-846. http://www.ncbi.nlm.nih.gov/pubmed/22150547, 10.1111/j.1530-0277.2011.01673.x.
234. Dunagan M., Chaudhry K., Samak G., Rao R.K. Acetaldehyde disrupts tight junctions in Caco-2 cell monolayers by a protein phosphatase 2A-dependent mechanism. American Journal of Physiology. Gastrointestinal and Liver Physiology 2012, 303(12):G1356-G1364. http://www.ncbi.nlm.nih.gov/pubmed/23064762, 10.1152/ajpgi.00526.2011.
235. Kirpich I.A., Feng W., Wang Y., Liu Y., Beier J.I., Arteel G.E., Falkner K.C., Barve S.S., McClain C.J. Ethanol and dietary unsaturated fat (corn oil/linoleic acid enriched) cause intestinal inflammation and impaired intestinal barrier defense in mice chronically fed alcohol. Alcohol (Fayetteville, N.Y.) 2013, 47(3):257-264. http://www.ncbi.nlm.nih.gov/pubmed/23453163, 10.1016/j.alcohol.2013.01.005.
236. Ge X., Lu Y., Leung T.M., Sørensen E.S., Nieto N. Milk osteopontin, a nutritional approach to prevent alcohol-induced liver injury. American Journal of Physiology. Gastrointestinal and Liver Physiology 2013, 304(10):G929-G939. http://www.ncbi.nlm.nih.gov/pubmed/23518682, 10.1152/ajpgi.00014.2013.
237. Forsyth C.B., Voigt R.M., Shaikh M., Tang Y., Cederbaum A.I., Turek F.W., Keshavarzian A. Role for intestinal CYP2E1 in alcohol-induced circadian gene-mediated intestinal hyperpermeability. American Journal of Physiology: Gastrointestinal and Liver Physiology 2013, 305(2):G185-G195. http://www.ncbi.nlm.nih.gov/pubmed/23660503, 10.1152/ajpgi.00354.2012.
238. Abdelmegeed M.A., Banerjee A., Jang S., Yoo S.H., Yun J.W., Gonzalez F.J., Keshavarzian A., Song B.J. CYP2E1 potentiates binge alcohol-induced gut leakiness, steatohepatitis, and apoptosis. Free Radical Biology and Medicine 2013, 65:1238-1245. http://www.ncbi.nlm.nih.gov/pubmed/24064383, 10.1016/j.freeradbiomed.2013.09.009.
239. Cresci G.A., Bush K., Nagy L.E. Tributyrin supplementation protects mice from acute ethanol-induced gut injury. Alcoholism, Clinical and Experimental Research 2014, 38(6):1489-1501. http://www.ncbi.nlm.nih.gov/pubmed/24890666, 10.1111/acer.12428.
240. Spruss A., Bergheim I. Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. Journal of Nutritional Biochemistry 2009, 20(9):657-662. http://www.ncbi.nlm.nih.gov/pubmed/19679262, 10.1016/j.jnutbio.2009.05.006.
241. Spruss A., Kanuri G., Stahl C., Bischoff S.C., Bergheim I. Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function. Laboratory Investigation: a Journal of Technical Methods and Pathology 2012, 92(7):1020-1032. http://www.ncbi.nlm.nih.gov/pubmed/22525431, 10.1038/labinvest.2012.75.
242. Ritze Y., Bárdos G., Claus A., Ehrmann V., Bergheim I., Schwiertz A., Bischoff S.C. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PloS One 2014, 9(1):e80169. http://www.ncbi.nlm.nih.gov/pubmed/24475018, 10.1371/journal.pone.0080169.